Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development

Author(s): Dane M. Springer

Volume 7, Issue 3, 2001

Page: [181 - 198] Pages: 18

DOI: 10.2174/1381612013398275

Price: $65


Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s- PLA2 that have been reported to be in late-stage development.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy